Sanara MedTech (SMTI) Investor presentation summary

Strategic focus and business model

• Transitioned to a pure-play surgical solutions business, discontinuing non-core segments to focus on the operating room setting and three core technologies: CellerateRX®, BIASURGEⓇ, and OsStic™.

• Business model is hospital-direct, insulating from reimbursement risk and leveraging Medicare's bundled payment system.

• Hybrid sales model combines a growing distributor network with a field sales team, enabling national reach and local expertise without proportional headcount increases.

Financial performance and growth

• Achieved record net revenue of $103.1M in 2025, with 19% year-over-year growth and a 51% seven-year CAGR.

• Gross margin reached 93% in 2025, with adjusted EBITDA of $17.0M and operating income of $7.3M.

• FY26 net revenue forecast is $116–$121M, representing 13–17% projected growth.

• Cash position at $13.6M and long-term debt at $46.2M as of March 31, 2026.

Product portfolio and innovation

• CellerateRX® is a market leader in activated collagen, with ~40% market share, strong clinical evidence, and proven reduction in surgical site infections.

• BIASURGEⓇ, a no-rinse antimicrobial irrigation solution, secured an Innovative Technology contract with VizientⓇ, expanding access to a large hospital network.

• OsStic™ is an FDA 'Breakthrough Device' synthetic bone adhesive targeting periarticular fractures, with launch expected in 1Q27.

• Additional products include tissue repair and bone fusion solutions, supporting a broad surgical workflow.